For your patients with 1L DLBCL, NOS or HGBL, and IPI 2-5,
For your patients with 1L DLBCL, NOS or HGBL, and IPI 2-5,
*Based on IQVIA claims data for 1L DLBCL cases Jan 2025-Nov 2025, with IPI status informed by Flatiron Health EHR data.
What could this mean for your patients?
CATEGORY 1
TREATMENT OPTION
National Comprehensive Cancer Network® (NCCN®) recommends polatuzumab vedotin-piiq (POLIVY) + R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) as an NCCN Category 1 treatment option across all stages of DLBCL for certain‡ patients (regardless of the COO).2
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
For your patients with 1L DLBCL, NOS or HGBL, and IPI 2-5,
What could this mean for your patients?
*Based on IQVIA claims data for 1L DLBCL cases Jan 2025-Nov 2025, with IPI status by Flatiron Health EHR data.
CATEGORY 1
TREATMENT OPTION
National Comprehensive Cancer Network® (NCCN®) recommends polatuzumab vedotin-piiq (POLIVY) + R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) as an NCCN Category 1 treatment option across all stages of DLBCL for certain‡ patients (regardless of the COO).2
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
POLIVY + R-CHP is approved for 1L DLBCL, NOS or HGBL and IPI ≥ 2.1
POLIVY (polatuzumab vedotin-piiq) is a CD79b-directed antibody-drug conjugate indicated in combination with R-CHP (a rituximab product, cyclophosphamide, doxorubicin, prednisone) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or high-grade B-cell lymphoma with IPI ≥2.
See clinical outcomes from the POLARIX trial, a double-blind, randomized, multicenter Phase 3 study evaluating POLIVY (polatuzumab vedotin-piiq) plus R-CHP versus R-CHOP in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL). In the trial, the POLIVY + R-CHP arm demonstrated statistically significant improvement in the primary endpoint of progression-free survival (PFS) versus R-CHOP (HR=0.73 [95% CI: 0.57, 0.95; p=0.0177]). POLIVY + R-CHP has the longest exploratory follow-up of any approved 1L DLBCL regimen vs R-CHOP.
POLIVY (polatuzumab vedotin-piiq) plus R-CHP is administered as a fixed-duration therapy over six, 21-day cycles. For detailed dose modifications, handling, and scheduling see dosing & administration.
Serious and sometimes fatal adverse reactions can occur with POLIVY treatment. Peripheral neuropathy, infusion-related reactions, myelosuppression, serious and opportunistic infections, progressive multifocal leukoencephalopathy (PML), tumor lysis syndrome, hepatotoxicity, infusion site extravasation injury, and embryo-fetal toxicity can occur with POLIVY treatment. The most common adverse reactions (≥20%), excluding laboratory abnormalities, are peripheral neuropathy, nausea, fatigue, diarrhea, constipation, alopecia, and mucositis. Grade 3 to 4 laboratory abnormalities (≥10%) are lymphopenia, neutropenia, hyperuricemia, and anemia. For full safety details, please refer to the safety section.
†Lives covered by Medicare Fee-for-Service, Medicare Advantage, and Commercial Plans. Specific coverage may vary for individuals and plans. Insurer/payer policies are subject to change. Data as of March 2026.
‡Category 1 treatment option for patients with previously untreated stage I-II (without extensive mesenteric disease) diffuse large B-cell lymphoma and smIPI score >1 (regardless of the COO); Category 1 preferred treatment option for patients with previously untreated stage II (with extensive mesenteric disease) or stage III-IV diffuse large B-cell lymphoma and IPI score ≥2 (regardless of the COO).2
1L = first-line; CI = confidence interval; COO = cell of origin; DLBCL = diffuse large B-cell lymphoma; HGBL = high-grade B-cell lymphoma; HR = hazard ratio; IPI = International Prognostic Index; ITT = intention-to-treat; NCCN = National Comprehensive Cancer Network® (NCCN®); NOS = not otherwise specified; OS = overall survival; PFS = progression-free survival; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP = rituximab, cyclophosphamide, doxorubicin, and prednisone; smIPI = stage-modified International Prognostic Index.
POLIVY Prescribing Information. Genentech, Inc.
POLIVY Prescribing Information. Genentech, Inc.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed May 20, 2026. To view the most recent and complete version of the guidelines, go online to NCCN.org
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed May 20, 2026. To view the most recent and complete version of the guidelines, go online to NCCN.org
Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858. doi:10.1056/NEJMra2027612
Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858. doi:10.1056/NEJMra2027612
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620
Maurer MJ, Habermann TM, Shi Q, et al. Utility of 2-year PFS24 to predict subsequent outcomes for patients with DLBCL enrolled on randomized clinical trials: findings from a surrogate endpoint in aggressive lymphoma (SEAL) analysis of individual patient data from 5853 patients. Blood. 2018;128:3027.
Maurer MJ, Habermann TM, Shi Q, et al. Utility of 2-year PFS24 to predict subsequent outcomes for patients with DLBCL enrolled on randomized clinical trials: findings from a surrogate endpoint in aggressive lymphoma (SEAL) analysis of individual patient data from 5853 patients. Blood. 2018;128:3027.
Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019;15(9):1021-1034.
Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019;15(9):1021-1034.
Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229-1236. doi:10.1634/theoncologist.2018-0490
Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229-1236. doi:10.1634/theoncologist.2018-0490
Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175. doi:10.1186/s13045-020-01011-z
Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175. doi:10.1186/s13045-020-01011-z
Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041-2048.
Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041-2048.
Kanas G, Ge W, Quek R, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2021;63(1):54-63.
Kanas G, Ge W, Quek R, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2021;63(1):54-63.
Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9. doi:10.1038/s41408-020-00403-1
Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9. doi:10.1038/s41408-020-00403-1
Shi X, Liu X, Li X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964.
Shi X, Liu X, Li X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964.
Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5):1120-1129. doi:10.1093/annonc/mdy113
Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5):1120-1129. doi:10.1093/annonc/mdy113
Fanale D, Bronte G, Passiglia F, et al. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015;2015:690916.
Fanale D, Bronte G, Passiglia F, et al. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015;2015:690916.
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363.
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363.
Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87.
Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87.
Poletto S, Novo M, Paruzza L, et al. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.
Poletto S, Novo M, Paruzza L, et al. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.
US Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry. December 2018. Accessed February 23, 2024. https://www.fda.gov/media/71195/download
US Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry. December 2018. Accessed February 23, 2024. https://www.fda.gov/media/71195/download
Data on File. South San Francisco, CA: Genentech, Inc.
Data on File. South San Francisco, CA: Genentech, Inc.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. doi:10.1200/JCO.2013.54.8800
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. doi:10.1200/JCO.2013.54.8800
MMIT and HLI database as of March 2026.
MMIT and HLI database as of March 2026.
Salles G, Morschhauser F, Sehn LH, et al. Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. Presented at: 66th ASH Annual Meeting; December 7-10, 2024; San Diego, CA.
Salles G, Morschhauser F, Sehn LH, et al. Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. Presented at: 66th ASH Annual Meeting; December 7-10, 2024; San Diego, CA.
Center for Drug Evaluation and Research. BLA 761121-S008 Multi-Disciplinary Review and Evaluation—Polivy (polatuzumab vedotin). US Food and Drug Administration. April 18, 2023. Accessed January 10, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761121Orig1s008MultidisciplineR.pdf
Center for Drug Evaluation and Research. BLA 761121-S008 Multi-Disciplinary Review and Evaluation—Polivy (polatuzumab vedotin). US Food and Drug Administration. April 18, 2023. Accessed January 10, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761121Orig1s008MultidisciplineR.pdf
Morschhauser F, Salles G, Sehn LH, et al. Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol. 2025;43(35):3698-3705. doi:10.1200/JCO-25-00925
Morschhauser F, Salles G, Sehn LH, et al. Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol. 2025;43(35):3698-3705. doi:10.1200/JCO-25-00925
Lue JK, Bobbili PJ, Garg M, et al. Real world treatment patterns and clinical outcomes of patients with treatment naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States. Leuk Res. 2025;159:108117.doi:10.1016/j.leukres.2025.108117
Lue JK, Bobbili PJ, Garg M, et al. Real world treatment patterns and clinical outcomes of patients with treatment naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States. Leuk Res. 2025;159:108117.doi:10.1016/j.leukres.2025.108117
Hilton LK, Ngu HS, Collinge B, et al. Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(25):4164-4177. doi:10.1200/JCO.23.00570
Hilton LK, Ngu HS, Collinge B, et al. Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(25):4164-4177. doi:10.1200/JCO.23.00570
Hilton LK, Ngu HS, Collinge B, et al. Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(suppl):1-17. doi:10.1200/JCO.23.00570
Hilton LK, Ngu HS, Collinge B, et al. Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(suppl):1-17. doi:10.1200/JCO.23.00570
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(suppl):1-41. doi:10.1056/NEJMoa2115304
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(suppl):1-41. doi:10.1056/NEJMoa2115304
Morschhauser F, Salles G, Sehn LH, et al. Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol. 2025;43(suppl):1-14. doi:10.1200/JCO-25-0092530
Morschhauser F, Salles G, Sehn LH, et al. Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol. 2025;43(suppl):1-14. doi:10.1200/JCO-25-0092530
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.